Show simple item record

dc.contributor.authorStubberud, Anker
dc.contributor.authorFlaaen, Nikolas Melseth
dc.contributor.authorMcCrory, Douglas C.
dc.contributor.authorPedersen, Sindre Andre
dc.contributor.authorLinde, Mattias
dc.date.accessioned2020-04-17T11:28:29Z
dc.date.available2020-04-17T11:28:29Z
dc.date.created2019-06-04T15:10:25Z
dc.date.issued2019
dc.identifier.citationPain. 2019, 160 (4), 762-772.en_US
dc.identifier.issn0304-3959
dc.identifier.urihttps://hdl.handle.net/11250/2651519
dc.description.abstractBased on few clinical trials, flunarizine is considered a first-line prophylactic treatment for migraine in several guidelines. In this meta-analysis, we examined the pooled evidence for its effectiveness, tolerability, and safety. Prospective randomized controlled trials of flunarizine as a prophylaxis against migraine were identified from a systematic literature search, and risk of bias was assessed for all included studies. Reduction in mean attack frequency was estimated by calculating the mean difference (MD), and a series of secondary outcomes—including adverse events (AEs)—were also analyzed. The database search yielded 879 unique records. Twenty-five studies were included in data synthesis. We scored 31/175 risk of bias items as “high,” with attrition as the most frequent bias. A pooled analysis estimated that flunarizine reduces the headache frequency by 0.4 attacks per 4 weeks compared with placebo (5 trials, 249 participants: MD 20.44; 95% confidence interval 20.61 to 2 0.26). Analysis also revealed that the effectiveness of flunarizine prophylaxis is comparable with that of propranolol (7 trials, 1151 participants, MD 20.08; 95% confidence interval 20.34 to 0.18). Flunarizine also seems to be effective in children. The most frequent AEs were sedation and weight increase. Meta-analyses were robust and homogenous, although several of the included trials potentially suffered from high risk of bias. Unfortunately, reporting of AEs was inconsistent and limited. In conclusion, pooled analysis of data from partially outdated trials shows that 10-mg flunarizine per day is effective and well tolerated in treating episodic migraine—supporting current guideline recommendations.en_US
dc.language.isoengen_US
dc.publisherLippincott, Williams & Wilkinsen_US
dc.titleFlunarizine as prophylaxis for episodic migraine: a systematic review with meta-analysisen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionacceptedVersionen_US
dc.source.pagenumber762-772en_US
dc.source.volume160en_US
dc.source.journalPainen_US
dc.source.issue4en_US
dc.identifier.doi10.1097/j.pain.0000000000001456
dc.identifier.cristin1702702
dc.description.localcode© 2019. This is the authors' accepted and refereed manuscript to the article. The final authenticated version is available online at: http://dx.doi.org/10.1097/j.pain.0000000000001456en_US
cristin.unitcode194,65,30,0
cristin.unitcode194,14,30,0
cristin.unitcode1920,16,1,0
cristin.unitnameInstitutt for nevromedisin og bevegelsesvitenskap
cristin.unitnameNTNU Universitetsbiblioteket
cristin.unitnameNasjonal kompetansetjeneste for hodepine
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode2


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record